Questions? Chat with the founder on WhatsApp

Chat with the founder on WhatsApp
Arthneeti
HomeRankingsIPOScreenerInstitutions
HomeRankingsIPOScreenerInstitutions
Vijaya Diagnost.Q1 FY27Healthcare Services
Home/Stocks/Vijaya Diagnost./Q1 FY27

Vijaya Diagnost. Q1 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,494P/E: 82.6Market Cap: ₹15.5K CrSector: Healthcare Services

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2
  • →Vijaya Diagnostic Centre plans to commission 9 new hub centres and 10-12 spoke centres in the upcoming year, continuing expansion in new markets.
  • →The company expects to sustain high double-digit revenue growth for FY27, building on a strong Q1 growth of 23%.
  • →Mid to long-term sustainable revenue growth is targeted around 15% annually over the next 3 to 5 years.
  • →Hyderabad cluster, which contributes ~67% of revenue, grew 17% year-on-year despite maturity, indicating strong organic growth.
  • →New tier-2 and metro locations like Rajahmundry, Tirupati, Kammam, Bangalore, Pune, and Kolkata are outperforming expectations, often breaking even within 2 quarters.
  • →Expansion focus includes dense networks in Pune, Bangalore, and Kolkata with plans to add 15 hubs across these metros over 12 months.
  • →Pathology volumes are scaling alongside radiology, supported by integrated offerings leading to higher tests per patient and better wallet share.
  • →Corporate wellness programs and retail wellness packages are additional growth drivers across tier-1 and tier-2 cities.

Margin guidance

Category 3
  • →Vijaya Diagnostic Centre delivered a strong Q1 FY27 with 23% revenue growth and is confident of high double-digit growth for the full year FY27.
  • →Mid to long-term sustainable growth is targeted at around 15% annually over 3 to 5 years.
  • →The company expects a new normal growth rate of approximately 20% based on successful expansion outside Hyderabad and Andhra clusters.
  • →Mature centres grew at 16% in Q1, with new centres contributing 6-6.5% revenue year-on-year.
  • →EBITDA margins are expected to be maintained above 40%, despite ongoing expansion and new hubs coming online.
  • →Operating leverage in existing clusters supports margin stability even as new hubs scale up.
  • →PAT margin held steady at 23% in Q1 FY27, reflecting profitability improvements.
  • →Management emphasizes confidence in replicating growth strategies across new clusters and deeper market penetration.

3 more insights locked — sign up free to unlock

Fundraise plans

  • →There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
  • →The company maintains a strong balance sheet with a surplus cash position of approximately INR 330 crores.
  • →Vijaya Diagnostic Centre emphasizes a disciplined approach to capital allocation and pursues expansions primarily through internal accruals and cash reserves.
  • →The capital expenditure of around INR 190 crores for expansion, including new hubs and infrastructure, is planned to be funded from the existing financial strength.
  • →No announcements or discussions about raising external funds via debt or equity were made during the call.

Order book

The document does not explicitly mention the current or expected order book or pending orders for Vijaya Diagnostic Centre Limited. However, from the provided information, relevant highlights related to expansion and capital expenditure include: - Network expansion including commissioning of new hubs and spokes in Hyderabad, AP, Pune, and Bengaluru. - Capex of approximately INR 30 crores for the new state-of-the-art hub in Bengaluru (JP Nagar) in Q1 FY27. - Plans to add 15 new hub centres across Pune, Bangalore, and Kolkata over next 12 months. - Intent to acquire land in Andhra Pradesh for a future state-of-the-art hub, with INR 190 crores capex guidance including acquisition cost. - The company maintains a strong cash position (~INR 330 crores) and disciplined capital allocation to support ongoing expansion. No specific figures or details about pending orders or orderbook were disclosed in the available transcript.

Capex plans

Yes
  • →Planned capex of approximately INR 190 to 195 crores over the next 12 months.
  • →Commissioning of 9 new hub centres and 10 to 12 spoke centres; 2 hubs and 6 spokes already commissioned in the current year.
  • →Major capex includes INR 30 crores for a state-of-the-art hub facility in JP Nagar, Bangalore, featuring advanced imaging equipment and a central lab.
  • →Acquisition of land (~INR 8-10 crores) in a key medical hub in Andhra Pradesh to set up a new state-of-the-art hub centre due to unavailability of leased properties.
  • →Setting up a state-of-the-art reference laboratory at Panjagutta included in the overall capex.
  • →Focus on expanding dense network model in metro cities and tier-2 locations with enhanced infrastructure and high-end radiology equipment.

How does Vijaya Diagnost. rank vs peers in Healthcare Services?

Pro feature
1Vijaya Diagnost.
Rev 2Mar 3
2Healthcare Services Company A
Rev 1Mar 2
3Healthcare Services Company B
Rev 2Mar 1
4Healthcare Services Company C
Rev 2Mar 3

See full Healthcare Services sector rankings

How does Vijaya Diagnost. rank in Healthcare Services?

Compare Vijaya Diagnost. against every Healthcare Services company (Q1 FY27) on revenue, margins and earnings-call signals.

View Healthcare Services leaderboard →

Related research

Read the full Q1 FY27 earnings insight — Vijaya Diagnost.

Other quarters — Vijaya Diagnost.

Q4 FY26Q3 FY26Q2 FY26Q1 FY26Q4 FY25Q3 FY25Q2 FY25Q1 FY25Q4 FY24Q3 FY24Q2 FY24Q1 FY24

Healthcare Services peers

Apollo Hospitals Enterprise Ltd · Q4 FY26Fortis Health. · Q1 FY27Syngene Intl. · Q4 FY26Dr Lal Pathlabs · Q1 FY27Narayana Hrudaya · Q1 FY27
Vijaya Diagnost. full stock analysisHealthcare Services sectorEarnings call directoryRankings dashboard

Questions about this analysis? Chat directly with the founder — real answers about the research, not a support bot.

WhatsApp the founder

Research team or advisory firm? Get earnings-call intelligence and ranking history as research inputs for your firm.

For Institutions

Arthneeti AI

AI-powered stock analysis from earnings call transcripts. Helping Indian investors make smarter decisions with data-driven insights.

Analysis

  • Stock Rankings
  • Sectors
  • Compare Stocks
  • IPO Dashboard
  • Stock Screener
  • Earnings Call Analysis
  • Stocks Under ₹500
  • Multibaggers

Tools

  • MF Overlap Checker
  • SIP Calculator
  • CAGR Calculator
  • FD vs Equity
  • All Calculators

Resources

  • Blog
  • Weekly Digest
  • Portfolio Analysis
  • Build Portfolio
  • Earnings Calendar
  • Q1 FY27 Earnings Hub

Company

  • Pricing
  • How Our Analysis Works
  • For Institutions
  • Terms of Service
  • Privacy Policy

Compare

  • vs Screener.in
  • vs Trendlyne
  • vs Tickertape
  • vs Moneycontrol Pro
+91 90841 32575 support@arthneeti.com Bengaluru, India

© 2026 Arthneeti AI. All rights reserved.

AI-analyzed data from 1,500+ company earnings calls

Continue your research

What Vijaya Diagnost.'s management said in earlier quarters

  • Q1 FY27 earnings call analysis →
  • Q4 FY26 earnings call analysis →
  • Q1 FY26 earnings call analysis →
  • Q3 FY25 earnings call analysis →

Others in Healthcare Services this season

  • Rainbow Childrens Medicare Ltd (Q1 FY27)

    Volume growth supported by planned addition of 2,500 beds over 5 years (~15% CAGR) (Page 10). Key concall takeaways from Rainbow Childrens Medicare Ltd's Q1…

  • Dr Lal Pathlabs (Q1 FY27)

    140 crore to Rs. Key concall takeaways from Dr Lal Pathlabs's Q1 FY27 earnings call — and how it ranks against sector peers.

  • Vimta Labs Ltd (Q1 FY27)

    The company's various business units are growing at almost double the industry's CAGR (8%-11%). Key concall takeaways from Vimta Labs Ltd's Q1 FY27 earnings…

  • Dr Agarwal's Hea (Q1 FY27)

    Q1 FY27 revenue from operations grew 26% year-on-year to INR614 crores, driven by both volume and value growth (~16% each). Key concall takeaways from Dr…

Compare:vs Apollo Hospitals Enterprise Ltdvs Max Healthcarevs Fortis Health.